Doublet Shows Activity in Rare, Aggressive Kidney Cancer

There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in patients with hereditary papillary renal cell carcinoma. The combination was approximately half as effective in patients with sporadic papillary renal cell carcinoma. Bevacizumab (Avastin) combined with erlotinib […]